pSivida Corp Announces Issuance of US Patent for Inserter to Be Used in Planned Phase III Uveitis Trials

WATERTOWN, MASS.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced it has been issued US patent No. 8,192,408 titled “Ocular Trocar Assembly” for a new inserter developed to facilitate administration of micro-drug delivery devices.
MORE ON THIS TOPIC